144 related articles for article (PubMed ID: 34367502)
1. Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis.
de Freitas Júnior JR; Ribeiro IB; de Moura DTH; Sagae VMT; de Souza GMV; de Oliveira GHP; Sánchez-Luna SA; de Souza TF; de Moura ETH; de Oliveira CPMS; Bernardo WM; de Moura EGH
World J Hepatol; 2021 Jul; 13(7):815-829. PubMed ID: 34367502
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis.
Popov VB; Thompson CC; Kumar N; Ciarleglio MM; Deng Y; Laine L
Dig Dis Sci; 2016 Sep; 61(9):2477-87. PubMed ID: 27207181
[TBL] [Abstract][Full Text] [Related]
3. Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis.
Shah RH; Vedantam S; Kumar S; Amin S; Pearlman M; Bhalla S
Obes Surg; 2023 Mar; 33(3):725-732. PubMed ID: 36633759
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses.
Zou ZY; Zeng J; Ren TY; Shi YW; Yang RX; Fan JG
J Clin Transl Hepatol; 2021 Jun; 9(3):353-363. PubMed ID: 34221921
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity.
Aoko O; Maharaj T; Boland F; Cheriyan D; Ryan J
Aliment Pharmacol Ther; 2024 Jan; 59(1):8-22. PubMed ID: 37986213
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
7. Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials.
Abuelazm MT; Mohamed I; Naeem A; Khlidj Y; Tanashat M; Katamesh BE; Abusuilik H; Altobaishat O; Abdelnabi M; Abdelazeem B
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):371-381. PubMed ID: 38407890
[TBL] [Abstract][Full Text] [Related]
8. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Abolfathi M; Mohd-Yusof BN; Hanipah ZN; Mohd Redzwan S; Yusof LM; Khosroshahi MZ
Complement Ther Med; 2020 Jan; 48():102273. PubMed ID: 31987257
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis.
Chandan S; Mohan BP; Khan SR; Facciorusso A; Ramai D; Kassab LL; Bhogal N; Asokkumar R; Lopez-Nava G; McDonough S; Adler DG
Obes Surg; 2021 Mar; 31(3):1271-1279. PubMed ID: 33409973
[TBL] [Abstract][Full Text] [Related]
10. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
11. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis.
Dajani AI; Popovic B
World J Clin Cases; 2020 Nov; 8(21):5235-5249. PubMed ID: 33269259
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.
Popov VB; Ou A; Schulman AR; Thompson CC
Am J Gastroenterol; 2017 Mar; 112(3):429-439. PubMed ID: 28117361
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Mahmoud A; Mohamed I; Abuelazm M; Ahmed AAS; Saeed A; Elshinawy M; Almaadawy O; Abdelazeem B
Proc (Bayl Univ Med Cent); 2024; 37(4):603-612. PubMed ID: 38910819
[No Abstract] [Full Text] [Related]
15. The effect of exercise training on clinical outcomes in patients with the metabolic syndrome: a systematic review and meta-analysis.
Ostman C; Smart NA; Morcos D; Duller A; Ridley W; Jewiss D
Cardiovasc Diabetol; 2017 Aug; 16(1):110. PubMed ID: 28854979
[TBL] [Abstract][Full Text] [Related]
16. The Combined Effect of Promoting the Mediterranean Diet and Physical Activity on Metabolic Risk Factors in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Malakou E; Linardakis M; Armstrong MEG; Zannidi D; Foster C; Johnson L; Papadaki A
Nutrients; 2018 Oct; 10(11):. PubMed ID: 30366431
[TBL] [Abstract][Full Text] [Related]
17. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding.
Folini L; Veronelli A; Benetti A; Pozzato C; Cappelletti M; Masci E; Micheletto G; Pontiroli AE
Acta Diabetol; 2014; 51(3):361-8. PubMed ID: 24085682
[TBL] [Abstract][Full Text] [Related]
18. Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Song T; Jia Y; Li Z; Wang F; Ren L; Chen S
Diabetes Ther; 2021 Jun; 12(6):1735-1749. PubMed ID: 34002333
[TBL] [Abstract][Full Text] [Related]
19. The Effect of the Mediterranean Diet on Metabolic Health: A Systematic Review and Meta-Analysis of Controlled Trials in Adults.
Papadaki A; Nolen-Doerr E; Mantzoros CS
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33143083
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
